Company: INDP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001641172-25-023490
Chunk: 46

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 46
---
, 2025);                                                                                                                           |
|:--|:-------------------------------------------------------------------------------------------------------------------------------------|
| ● | our Current Reports on                                                                                                               
 Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports that 
 relate to such items) filed with the SEC on January 14, 2025, January 31, 2025, February 12, 2025, March 13, 2025, May 14, 2025,     
 June 11, 2025, June 13, 2025, June 26, 2025, July 1, 2025, July 16, 2025 and July 29, 2025;                                          |
| ● | our annual Proxy Statement                                                                                                           
 on Schedule 14A relating to our annual meeting of stockholders, filed on April 28, 2025 (with respect to those portions incorporated 
 by reference into our Annual Report on Form 10-K for the year ended December 31, 2024).                                              |
| ● | the description of our                                                                                                               
 shares of common stock contained in Item 1 of the Registration Statement on Form 8-A (File No. 001-40652), filed with the SEC on     
 July 23, 2021, including any amendment or report filed for the purpose of updating such description.                                 |

We are not, however, incorporating, in each case, any documents or information that we are deemed to furnish and not file in accordance with SEC rules.

Any statement contained in any document incorporated by reference herein will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or any prospectus supplement modifies or supersedes such statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.

All reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act in this prospectus prior to the termination of this offering, including all such documents we may file with the SEC after the date of the initial registration statement of which this prospectus is a part and prior to the effectiveness of the registration statement, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be